These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33835337)

  • 1. Large-volume cell-free and concentrated ascites reinfusion therapy improves venous flow in patients with liver cirrhosis.
    Matsumoto N; Ogawa M; Kanda T; Matsuoka S; Moriyama M; Matsusaki K
    J Med Ultrason (2001); 2021 Jul; 48(3):315-322. PubMed ID: 33835337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal vein measurement using ultrasonography in patients with cirrhotic ascites and congestive heart failure.
    Kaneko M; Matsumoto N; Kumagawa M; Watanabe Y; Hirayama M; Nakagawara H; Yamamoto T; Ogawa M; Moriyama M
    J Med Ultrason (2001); 2021 Apr; 48(2):225-234. PubMed ID: 33768355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Portal hemodynamics after large-volume paracentesis in patients with liver cirrhosis and tense ascites.
    Sagarad SV; Chawla YK; Dhiman RK
    Dig Dis Sci; 1998 Nov; 43(11):2470-2. PubMed ID: 9824136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites.
    Ito T; Hanafusa N; Soneda N; Isoai A; Kobayashi R; Torii N; Kato M
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3224-3232. PubMed ID: 34250635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
    Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
    Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites.
    Yokomichi N; Imai K; Sakamoto M; Horiki M; Yamauchi T; Miwa S; Inoue S; Uneno Y; Suzuki H; Wada T; Ichikawa Y; Morita T
    BMC Cancer; 2022 Feb; 22(1):218. PubMed ID: 35227250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.
    Yorioka N; Namisaki T; Shibamoto A; Suzuki J; Kubo T; Iwai S; Tomooka F; Tanaka M; Takeda S; Fujimoto Y; Enomoto M; Muarata K; Inoue T; Tsuji Y; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Kawaratani H; Akahane T; Mitoro A; Yamazaki M; Yoshiji H
    In Vivo; 2023; 37(3):1226-1235. PubMed ID: 37103093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship among volume of paracentesis, portal blood flow and renal resistive index, evaluated by duplex Doppler ultrasonography in cirrhosis with tense ascites.
    Caruso G; Catalano D; Carpinteri G; Di Fazzio S; Mazzone O
    Recenti Prog Med; 1996 Apr; 87(4):164-6. PubMed ID: 8643878
    [No Abstract]   [Full Text] [Related]  

  • 9. Doppler hemodynamic study in portal hypertension and hepatic encephalopathy.
    Perisic M; Ilic-Mostic T; Stojkovic M; Culafic D; Sarenac R
    Hepatogastroenterology; 2005; 52(61):156-60. PubMed ID: 15783018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Refractory Ascites for Liver Transplant Candidates: A Novel Cell-free and Concentrated Ascites Reinfusion Therapy.
    Shimizu S; Ohira M; Nakano R; Imaoka Y; Sato K; Tahara H; Ide K; Kobayashi T; Kuroda S; Ono H; Tanaka Y; Ohdan H
    Transplant Proc; 2019 Oct; 51(8):2740-2744. PubMed ID: 31563243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis.
    Kozaki K; IInuma M; Takagi T; Fukuda T; Sanpei T; Terunuma Y; Yatabe Y; Akano K
    Ther Apher Dial; 2016 Aug; 20(4):376-82. PubMed ID: 27523078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.
    Hanada R; Yokomichi N; Kato C; Miki K; Oyama S; Morita T; Kawahara R
    Support Care Cancer; 2018 May; 26(5):1489-1497. PubMed ID: 29168037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study.
    Yamada Y; Inui K; Hara Y; Fuji K; Sonoda K; Hashimoto K; Kamijo Y
    Sci Rep; 2019 Jul; 9(1):10195. PubMed ID: 31308465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Portal and splenic hemodynamics in cirrhotic patients: relationship between esophageal variceal bleeding and the severity of hepatic failure.
    Kayacetin E; Efe D; Doğan C
    J Gastroenterol; 2004 Jul; 39(7):661-7. PubMed ID: 15293137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CART: Cell-free and Concentrated Ascites Reinfusion Therapy against malignancy-related ascites.
    Ito T; Hanafusa N
    Transfus Apher Sci; 2017 Oct; 56(5):703-707. PubMed ID: 28916401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascites management by cell-free concentrated ascites reinfusion therapy during recovery from drug-induced acute liver injury: a case report.
    Yasuda K; Asou M; Asakawa T; Araki M
    J Med Case Rep; 2020 Oct; 14(1):192. PubMed ID: 33050943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.
    Namisaki T; Tsuji Y; Kitade M; Yorioka N; Fujinaga Y; Sawada Y; Nishimura N; Kitagawa K; Inoue T; Takaya H; Kaji K; Kawaratani H; Moriya K; Akahane T; Mitoro A; Yoshiji H
    In Vivo; 2022; 36(3):1477-1484. PubMed ID: 35478114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites.
    Rivolta R; Maggi A; Cazzaniga M; Castagnone D; Panzeri A; Solenghi D; Lorenzano E; di Palo FQ; Salerno F
    Hepatology; 1998 Nov; 28(5):1235-40. PubMed ID: 9794906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-free and concentrated ascites reinfusion therapy versus large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study.
    Hanai T; Kawaratani H; Nagano J; Suii H; Sakamaki A; Arase Y; Nakanishi H; Kogiso T; Okubo T; Miwa T; Shimizu S; Hige S; Atsukawa M; Shimizu M; Kurosaki M; Terai S; Kagawa T; Tokushige K; Yoshiji H
    Hepatol Res; 2023 Mar; 53(3):238-246. PubMed ID: 36433862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Doppler evaluation of the splenoportal venous system in various stages of cirrhosis: differences between right and left portal veins.
    Kutlu R; Karaman I; Akbulut A; Baysal T; Sigirci A; Alkan A; Aladag M; Seckin Y; Saraç K
    J Clin Ultrasound; 2002; 30(9):537-43. PubMed ID: 12404519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.